Analyst Research

Report Title Price
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

EU Agency Rejects Sanofi SA's and Isis Pharmaceuticals Inc's Cholesterol Drug-Reuters


Friday, 14 Dec 2012 09:08am EST 

Reuters reported that European regulators have recommended against approval of Sanofi SA's and Isis Pharmaceutical Inc's drug Kynamro for treatment of a rare genetic disorder that causes unusually high cholesterol. The European Medicines Agency said it was concerned about the medicine‚Äôs safety, noting that a high proportion of patients stopped taking it within two years, mainly due to side effects such as flu-like symptoms, injection site reactions and liver toxicity. 

Company Quote

34.01
-0.56 -1.62%
17 Apr 2014